在复发性神经内分泌性宫癌中对trastuzumab deruxtecan的异常反应:一个病例报告

相关实验视频

Updated: Sep 15, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K

Lauren Tostrud¹, Brooke E Howitt², Margaret Mills³

¹Stanford University, Department of Obstetrics & Gynecology. 900 Blake Wilbur Drive, Palo Alto, CA 94304, United States.

Gynecologic oncology reports

|July 18, 2025

概括

特拉斯图祖马布德鲁克斯泰干 (T-DXd) 在患有复发性神经内分泌性宫癌 (NECC) 的患者中实现了完全反应. 这表明T-DXd在罕见的癌症中有效,即使在先前使用毒素酶I抑制剂治疗后也是如此.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
生物标志物发现发现

背景情况:

神经内分泌宫癌 (NECC) 是一种罕见的,具有攻击性的癌症,对复发性疾病的治疗选择有限.
特拉斯图祖马布德鲁克斯泰坎 (T-DXd) 是一种已批准用于治疗HER2+转移性固体瘤的抗体-药物结合物.

相关概念视频

02:56

Treatment Resistant Cancers

3.4K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

3.4K

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...